Grade C Patent Portfolios
10 companies with average patent strength
Grade C means average patent portfolios with moderate coverage and mixed expiration timelines. Patent Strength Scores are calculated using USPTO PatentsView data.
All Grade C Companies
| Company | Patents | Score | Expiring 2yr | Expiring 5yr |
|---|---|---|---|---|
| Samsung | 130 | 61 | 7 | 19 |
| Huawei | 120 | 56 | 6 | 16 |
| 110 | 56 | 5 | 14 | |
| Microsoft | 100 | 55 | 4 | 10 |
| Canon | 90 | 52 | 3 | 9 |
| Amazon | 90 | 52 | 1 | 12 |
| Apple | 95 | 51 | 5 | 12 |
| General Electric | 85 | 51 | 4 | 7 |
| Qualcomm | 75 | 51 | 0 | 10 |
| Toyota | 70 | 50 | 1 | 3 |
Frequently Asked Questions
Grade C (Average) indicates average patent portfolios with moderate coverage and mixed expiration timelines. The grade is based on portfolio size (30%), claims breadth (25%), time remaining (25%), and portfolio diversity (20%).
10 of 100 tracked companies currently have a Grade C Patent Strength Score, holding a combined 965 patents.
Grade C companies have weaker IP protection. Investors should assess whether the company relies on patents for competitive advantage, as their portfolio may not deter competitors or generate licensing revenue.
/methodology
The this entity category groups every U.S. pharmaceutical patent expirations entity sharing this attribute. The list above is the data; the paragraphs below explain what the grouping means against the broader the FDA Orange Book and USPTO patent records distribution and how to read the relative rankings within the category.
For readers using this category as a starting point, the per-entity detail pages linked from the table above carry the underlying the FDA Orange Book and USPTO patent records data in full. The category-level view is the filter; the per-entity pages are the actual answer.
Source: USPTO patent search, 2026.